A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial

Figures

• 

  Figure.. Summary of primary findings in the KABUKI trial. A, Primary end point: week 48 to baseline ratio of pulmonary vascular resistance (PVR). Geometric mean ratio of PVR (week 48 to baseline) was 0.93 (95% CI, 0.86–1.01) in the edoxaban group and 1.01 (95% CI, 0.93–1.10) in the warfarin group, resulting in a treatment effect (ratio of geometric means for edoxaban compared with warfarin of 0.920 [95% CI, 0.820–1.032]; P<0.0001 for noninferiority). B, Exploratory outcome: change in PVR at week 48 from baseline. The least squares (LS) mean difference between the edoxaban group and warfarin group (treatment effect) of change in PVR at week 48 from baseline was −0.155 Wood Units (95% CI, −0.416 to 0.107; P=0.242). C, Secondary end point: changes in 6-minute walk distance at week 48 from baseline. The LS mean difference between the edoxaban group and warfarin group (treatment effect) of change in 6-minute walk distance at week 48 was 5.6 m (95% CI, –16.4 to 27.6; P=0.612). D, Secondary end point: changes in NT-proBNP level at prespecified visits from baseline. The LS mean difference between the edoxaban group and warfarin group (treatment effect) of change in NT-proBNP level at week 48 from…